当前位置:
首页>产品中心>单抗/多抗>Urelumab ELISA Kit|乌瑞鲁单抗ELISA检测试剂盒(靶标:乌瑞鲁单抗酶联免疫检测试剂盒)
Urelumab ELISA Kit|乌瑞鲁单抗ELISA检测试剂盒(靶标:乌瑞鲁单抗酶联免疫检测试剂盒)
- 货号:RB9TDC336018
- 价格:面议
- 点击:357
产品介绍
产品参数
| 应用 | ELISA |
|---|
| 检测方法 | Colorimetric |
|---|
| 灵敏度 | 18.73 ng/mL |
|---|
| 检测范围 | 31.25 - 2, 000 ng/mL |
|---|
| 回收率 | 80-120% |
|---|
| 样本类型 | Plasma, Serum |
|---|
| 检测类型 | Quantitative |
|---|
| 稳定性和储存 | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. |
|---|
| 运输条件 | 2-8 ℃ |
|---|
| 登录号 | Q07011 |
|---|
| 背景信息 | Urelumab is a fully humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer-Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. In December 2008, enrolment was stopped for all urelumab studies following the occurrence of two hepatotoxicity-related deaths. Several years later, the clinical study on Urelumab was restarted. At present, the approval of the monoclonal antibody has not been disclosed in the relevant drug approval agency. |
|---|
| 别名 | BMS-663513, 934823-49-1 |
|---|
| 备注 | For Research Use Only. |
|---|
【仅供科学研究使用】
相关产品: